The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma
Open accessAbstract
BACKGROUND: Since sunitinib malate has shown activity in two uncontrolled studies in patients with metastatic renal-cell carcinoma, a comparison of the drug with interferon alfa in a phase 3 trial is warranted. METHODS: We enrolled 750 patients with previously untreated, metastatic renal-cell carcinoma in a multicenter, randomized, phase 3 trial to receive either repeated 6-week cycles of sunitinib (at a dose of 50 mg given orally once daily for 4 weeks, followed by 2 weeks without treatment) or interferon alfa (at a dose of 9 MU given subcutaneously three times weekly). The primary end point was progression-free survival. Secondary end points included the objective response rate, overall survival, patient-reported outcomes, and safety. RESULTS: The median progression-free survival was significantly longer in the sunitinib group (11 months) than in the interferon alfa group (5 months), corresponding to a hazard ratio of 0.42 (95% confidence interval, 0.32 to 0.54; P<0.001). Sunitinib was also associated with a higher objective response rate than was interferon alfa (31% vs. 6%, P<0.001). The proportion of patients with grade 3 or 4 treatment-related fatigue was significantly higher in the group treated with interferon alfa, whereas diarrhea was more frequent in the sunitinib group (P<0.05). Patients in the sunitinib group reported a significantly better quality of life than did patients in the interferon alfa group (P<0.001). CONCLUSIONS: Progression-free survival was longer and response rates were higher in patients with metastatic renal-cell cancer who received sunitinib than in those receiving interferon alfa (ClinicalTrials.gov numbers, NCT00098657 and NCT00083889 [ClinicalTrials.gov]).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Immunotherapy for advanced renal cell cancer
Coppin, C., Porzsolt, F., Autenrieth, M., Kumpf, J., Coldman, A., & Wilt, T. (2004) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001425.pub2 · Cited by 589
RetractedJemal, A., Bray, F., Center, M. M., Ferlay, J., Ward, E., & Forman, D. (2011) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20107 · Cited by 54,679
Global Cancer Statistics, 2002
Parkin, D. M., Bray, F., Ferlay, J., & Pisani, P. (2005) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.55.2.74 · Cited by 18,196
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Evaluation of survival data and two new rank order statistics arising in its consideration.
Mantel, N. (1966) · PubMed · Cited by 7,519
Cox, D. R., & Oakes, D. (2018) · Chapman & Hall/CRC eBooks · doi:10.1201/9781315137438 · Cited by 6,234
The functional assessment of cancer therapy scale: development and validation of the general measure
Cella, D. F., Tulsky, D. S., Gray, G., Sarafian, B., Linn, E., Bonomi, A., Silberman, M., Yellen, S. B., Winicour, P., & Brannon, J. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.3.570 · Cited by 6,020
The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis
Maxwell, P. H., Wiesener, M. S., Chang, G.-W., Clifford, S. C., Vaux, E. C., Cockman, M. E., Wykoff, C. C., Pugh, C. W., Maher, E. R., & Ratcliffe, P. J. (1999) · Nature · doi:10.1038/20459 · Cited by 5,180
Fitzmaurice, G. M., Laird, N. M., & Ware, J. H. (2011) · Wiley Series in Probability and Statistics · doi:10.1002/9781119513469 · Cited by 4,639
Yang, J. C., Haworth, L., Sherry, R. M., Hwu, P., Schwartzentruber, D. J., Topalian, S. L., Steinberg, S. M., Chen, H. X., & Rosenberg, S. A. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021491 · Cited by 2,697
Cited by
Items 201–219 of 219
Thyroid dysfunctions induced by tyrosine kinase inhibitors
Fallahi, P., Ferrari, S. M., Vita, R., Di Domenicantonio, A., Corrado, A., Benvenga, S., & Antonelli, A. (2014) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2014.913021 · Cited by 60
Mao, W., Wang, K., Wu, Z., Xu, B., & Chen, M. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-02114-2 · Cited by 48
Vanderhoek, M., Perlman, S. B., & Jeraj, R. (2013) · Journal of Nuclear Medicine · doi:10.2967/jnumed.112.113332 · Cited by 47
Signal integration and gene induction by a functionally distinct STAT3 phosphoform
Waitkus, M. S., Chandrasekharan, U. M., Willard, B., Tee, T. L., Hsieh, J. K., Przybycin, C. G., Rini, B. I., & DiCorleto, P. E. (2014) · Molecular and Cellular Biology · doi:10.1128/mcb.00034-14 · Cited by 45
Aflibercept in the Treatment of Metastatic Colorectal Cancer
Wang, T.-F., & Lockhart, A. C. (2012) · Clinical Medicine Insights: Oncology · doi:10.4137/cmo.s7432 · Cited by 44
Systemic low‐molecular weight drug delivery to pre‐selected neuronal regions
Campbell, M., Humphries, M. M., Kiang, A., Nguyen, A. T. H., Gobbo, O. L., Tam, L. C. S., Suzuki, M., Hanrahan, F., Ozaki, E., Farrar, G. ‐., et al. (2011) · EMBO Molecular Medicine · doi:10.1002/emmm.201100126 · Cited by 42
Clinical trials with anti‐angiogenic agents in hematological malignancies
Medinger, M., & Mross, K. (2010) · Journal of Angiogenesis Research · doi:10.1186/2040-2384-2-10 · Cited by 40
Mezrich, J. D., Nguyen, L. P., Kennedy, G., Nukaya, M., Fechner, J. H., Zhang, X., Xing, Y., & Bradfield, C. A. (2012) · PLoS ONE · doi:10.1371/journal.pone.0044547 · Cited by 40
Radiotherapy in combination with vascular-targeted therapies
Ciric, E., & Sersa, G. (2010) · Radiology and Oncology · doi:10.2478/v10019-010-0025-9 · Cited by 30
Costa, S., Bentley, C., Regier, D. A., McTaggart-Cowan, H., Mitton, C., Burgess, M. M., & Peacock, S. J. (2019) · BMC Public Health · doi:10.1186/s12889-019-7303-2 · Cited by 22
Lee, N., Lee, J. L., & Lee, J.-Y. (2023) · Targeted Oncology · doi:10.1007/s11523-023-00951-z · Cited by 20
Recent concepts of antiangiogenic therapy
Konno, H., Yamamoto, M., & Ohta, M. (2010) · Surgery Today · doi:10.1007/s00595-009-4150-2 · Cited by 16
Inhibiteurs de mTOR : temsirolimus et évérolimus dans le traitement du cancer du rein
Ravaud, A., Bernhard, J.-C., Gross-Goupil, M., Digue, L., & Ferriere, J.-M. (2010) · Bulletin du Cancer · doi:10.1684/bdc.2010.1069 · Cited by 14
The Gut Microbiome and Metastatic Renal Cell Carcinoma
Meza, L., Feng, M., Lee, K., Sperandio, R., & Pal, S. K. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12041502 · Cited by 12
Revisiting mechanisms of resistance to immunotherapies in metastatic clear-cell renal-cell carcinoma
Chatwal, M. S., Chahoud, J., & Spiess, P. E. (2023) · Cancer Drug Resistance · doi:10.20517/cdr.2023.09 · Cited by 12
Wu, X.-H., Wang, J.-Q., Wang, M.-D., Xiao, T., Wang, Y., Niu, J.-Y., Wang, L., Hou, D.-Y., Fu, B., Liu, Z., et al. (2024) · Biomaterials · doi:10.1016/j.biomaterials.2024.122550 · Cited by 9
Kidney cancer models for pre-clinical drug discovery: challenges and opportunities
Pohl, L., Friedhoff, J., Jurcic, C., Teroerde, M., Schindler, I., Strepi, K., Schneider, F., Kaczorowski, A., Hohenfellner, M., Duensing, A., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.889686 · Cited by 5
The Early Effect of Sunitinib on Insulin Clearance in Patients with Metastatic Renal Cell Carcinoma
Thijs, A. M. J., Tack, C. J., van der Graaf, W. T. A., Rongen, G. A., & van Herpen, C. M. L. (2016) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12797 · Cited by 5
37 Drugs that act on the immune system: cytokines and monoclonal antibodies
Vial, T., Descotes, J., Braun, F., & Behrend, M. (2007) · Side effects of drugs annual · doi:10.1016/s0378-6080(06)29037-8 · Cited by 3
Metadata
- Authors
- Motzer, R. J., Hutson, T. E., Tomczak, P., Michaelson, M. D., Bukowski, R. M., Rixe, O., Oudard, S., Negrier, S., Szczylik, C., Kim, S. T., Chen, I., Bycott, P. W., Baum, C. M., & Figlin, R. A.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2007-01-11
- Volume
- 356
- Issue
- 2
- Pages
- 115-124
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2149456801
- Cited by
- 5,775
- References
- 40
- FWCI
- 412.97
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.